Literature DB >> 2574673

Effect of urinary pH on the plasma and urinary kinetics of remoxipride in man.

E Widerlöv1, B Termander, M I Nilsson.   

Abstract

The influence of urinary pH on the plasma and urinary kinetics of remoxipride in man has been studied in an open crossover trial in ten healthy male volunteers. Ammonium chloride (urinary pH 5.2) and sodium hydrogen carbonate (urinary pH 7.8) were used as pretreatments on two occasions in randomized order. On each occasion remoxipride 50 mg solution was administered orally and plasma and urinary concentrations of the drug were determined by HPLC and plasma prolactin concentrations by RIA. Remoxipride was rapidly distributed in the body according to a one-compartment model. The mean plasma elimination half-life (t1/2) was 3.6 h in the ammonium chloride experiment and 6.2 h in the sodium hydrogen carbonate experiment. The mean plasma clearance of remoxipride was 141 and 89.9 ml.min-1 in the acidic and alkaline conditions, respectively, and the corresponding mean renal clearances were 58.5 ml.min-1 and 11.7 ml.min-1. The urinary excretion of remoxipride up to 72 h after drug administration was 43.1% and 12.3% following acidification and alkalinization, respectively. Remoxipride induced a similar rapid, transient elevation of plasma prolactin under both conditions. Thus, the urinary pH has a marked effect on the elimination kinetics of remoxipride. After an overdose, treatment with ammonium chloride might be valuable in hastening elimination of remoxipride from the body.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2574673     DOI: 10.1007/bf00558500

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

Review 1.  RENAL TUBULAR MECHANISMS FOR EXCRETION OF ORGANIC ACIDS AND BASES.

Authors:  I M WEINER; G H MUDGE
Journal:  Am J Med       Date:  1964-05       Impact factor: 4.965

2.  Non-ionic diffusion and the excretion of weak acids and bases.

Authors:  M D MILNE; B H SCRIBNER; M A CRAWFORD
Journal:  Am J Med       Date:  1958-05       Impact factor: 4.965

3.  CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates.

Authors:  A J Sedman; J G Wagner
Journal:  J Pharm Sci       Date:  1976-07       Impact factor: 3.534

4.  Urinary excretion kinetics of amphetamine in man.

Authors:  A H Beckett; M Rowland
Journal:  J Pharm Pharmacol       Date:  1965-10       Impact factor: 3.765

5.  Effects of remoxipride and some related new substituted salicylamides on rat brain receptors.

Authors:  H Hall; M Sällemark; E Jerning
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1986-01

6.  Remoxipride--a new potential antipsychotic compound. Tolerability and pharmacokinetics after single oral and intravenous administration in healthy male volunteers.

Authors:  M Grind; M I Nilsson; L Nilsson; G Oxenstierna; G Sedvall; A Wahlén
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain.

Authors:  S O Ogren; H Hall; C Köhler; O Magnusson; L O Lindbom; K Angeby; L Florvall
Journal:  Eur J Pharmacol       Date:  1984-07-20       Impact factor: 4.432

8.  Effect of urinary pH on the disposition of methadone in man.

Authors:  M I Nilsson; E Widerlöv; U Meresaar; E Anggård
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

  8 in total
  4 in total

1.  Pharmacokinetics and effects on prolactin of remoxipride in patients with tardive dyskinesia.

Authors:  E Widerlöv; U Andersson; C von Bahr; M I Nilsson
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

2.  Remoxipride: pharmacokinetics and effect on plasma prolactin.

Authors:  G Movin-Osswald; M Hammarlund-Udenaes
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

3.  The pharmacokinetics of remoxipride and metabolites in patients with various degrees of renal function.

Authors:  G Movin-Osswald; J Boelaert; M Hammarlund-Udenaes; L B Nilsson
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

Review 4.  Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia.

Authors:  A N Wadworth; R C Heel
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.